Search

Your search keyword '"Olowu, Wasiu A."' showing total 153 results
Start Over Author "Olowu, Wasiu A."
153 results on '"Olowu, Wasiu A."'

4. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence

Author

Rossing, Peter, Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A., Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R., Wanner, Christoph, Wilkens, Katy G., Zoungas, Sophia, Craig, Jonathan C., Tunnicliffe, David J., Tonelli, Marcello A., Cheung, Michael, Earley, Amy, and de Boer, Ian H.

Published
2022
Full Text
View/download PDF

5. Sickle cell nephropathy: insights into the pediatric population

Author

Adebayo, Oyindamola C., Van den Heuvel, Lambertus P., Olowu, Wasiu A., Levtchenko, Elena N., and Labarque, Veerle

Subjects
Sickle cell anemia -- Diagnosis -- Risk factors, Pediatric research, Health
Abstract

The life expectancy of individuals with sickle cell disease has increased over the years, majorly due to an overall improvement in diagnosis and medical care. Nevertheless, this improved longevity has resulted in an increased prevalence of chronic complications such as sickle cell nephropathy (SCN), which poses a challenge to the medical care of the patient, shortening the lifespan of patients by 20-30 years. Clinical presentation of SCN is age-dependent, with kidney dysfunction slowly beginning to develop from childhood, progressing to chronic kidney disease and kidney failure during the third and fourth decades of life. This review explores the epidemiology, pathology, pathophysiology, clinical presentation, and management of SCN by focusing on the pediatric population. It also discusses the factors that can modify SCN susceptibility., Author(s): Oyindamola C. Adebayo [sup.1] [sup.2] , Lambertus P. Van den Heuvel [sup.1] [sup.3] , Wasiu A. Olowu [sup.4] , Elena N. Levtchenko [sup.1] [sup.5] , Veerle Labarque [sup.2] [sup.6] [...]

Published
2022
Full Text
View/download PDF

7. Management of idiopathic childhood nephrotic syndrome in sub-Saharan Africa: Ibadan consensus statement

Author

Ashuntantang, Gloria, Georgette, Guemkam, Adu, Dwamoa, Adabayeri, Victoria May, Boima, Vincent, Osafo, Charlotte, Tannor, Elliot Koranteng, Okyere, Perditer, Antwi, Sampson, Plange-Rhule, Jacob, Mamven, Manmak, Ajayi, Samuel, Anigilaje, Emmanuel, Okoye, Ogochukwu, Okperi, Ofejiro, Ighosewe, Okiroro, Ulasi, Ifeoma, Muoneke, Uzoamaka, Odetunde, Odutola, Okafor, Henrietta U., Salako, Babatunde, Ademola, Adebowale, Amodu, Kemi, Raji, Yemi, Adanze, Asinobi O., Arogundade, Fatiu, Olowu, Wasiu, Olanrewaju, Timothy Olusegun, Adedoyin, Olanrewaju, Obiagwu, Patience, Abdu, Aliyu, Solarin, Adaobi, Amira, Oluwatoyin, Esezobor, Christopher, Odenigbo, Charles, Jisieike-Onuigbo, Nonyelum, Musa, Adesola, Audu, Rosemary, Jinadu, Olanrewaju, Adetunji, Adewale E., Makusidi, Muhammad, Jiya Bello, Fatima Nma, Awobusuyi, Jacob Olugbenga, McCulloch, Mignon, Nourse, Peter, Furia, Francis Frederick, Ruggajo, Paschal, Shoo, Jacqueline, Kalyesubula, Robert, Kansiime, Grace, Batte, Anthony, Parekh, Rulan S., Noone, Damien, Vasilevska-Ristovska, Jovanka, Banh, Tonny H.M., Ojo, Akinlolu O., Wilson, Jillian, Smith, Donna, Ilori, Titilayo, Gbadegesin, Rasheed, Ademola, Adebowale D., Anigilaje, Emmanuel A., Jiya-Bello, Fatima N., Furia, Francis F., and Tannor, Elliot K.

Published
2021
Full Text
View/download PDF

10. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

Author

de Boer, Ian H., Rossing, Peter, Caramori, M. Luiza, Chan, Juliana C. N., Heerspink, Hiddo J. L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A., Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R., Wanner, Christoph, Wilkens, Katy G., Zoungas, Sophia, Jadoul, Michel, Winkelmayer, Wolfgang C., Tonelli, Marcello A., Craig, Jonathan C., Strippoli, Giovanni F. M., Tunnicliffe, David J., Higgins, Gail Y., Natale, Patrizia, Cooper, Tess E., and Willis, Narelle S.

Subjects
lifestyle, self-management, GLUCOSE COTRANSPORTER 2, ASSESSING GLYCEMIC CONTROL, GLP-1 receptor agonist, glycemic targets, INSULIN-DEPENDENT DIABETICS, renin-angiotensin system, GLOMERULAR-FILTRATION-RATE, MODERATE SODIUM RESTRICTION, DIETARY-PROTEIN RESTRICTION, ESTABLISHED CARDIOVASCULAR-DISEASE, systematic review, evidence-based, teambased care, CONVERTING-ENZYME-INHIBITION, KDIGO, hemodialysis, HbAlc, SGLT2 inhibitor, URINARY ALBUMIN EXCRETION, models of care, angiotensin II receptor blocker, glycemia, nutrition, angiotensin-converting enzyme inhibitor, Nephrology, INTENSIFIED MULTIFACTORIAL INTERVENTION, dialysis, glycemic monitoring, metformin, guideline, chronic kidney disease
Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating diabetes and CKD. Topic areas for which recommendations are updated include: Chapter 1: Comprehensive care in patients with diabetes and CKD and Chapter 4: Glucose-lowering therapies in patients with type 2 diabetes (T2D) and CKD. Previous chapters on Glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), Lifestyle interventions in patients with diabetes and CKD (Chapter 3), and Approaches to management of patients with diabetes and CKD (Chapter 5) have been deemed current and their content has remained un- changed. Development of this guideline update followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach. Limitations of the evidence are discussed and areas of future research are also presented. The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating diabetes and CKD. Topic areas for which recommendations are updated include: Chapter 1: Comprehensive care in patients with diabetes and CKD and Chapter 4: Glucose-lowering therapies in patients with type 2 diabetes (T2D) and CKD. Previous chapters on Glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), Lifestyle interventions in patients with diabetes and CKD (Chapter 3), and Approaches to management of patients with diabetes and CKD (Chapter 5) have been deemed current and their content has remained unchanged. Development of this guideline update followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed and areas of future research are also presented.

Published
2022
Full Text
View/download PDF

11. Diabetes Management in Chronic Kidney Disease:Synopsis of the KDIGO 2022 Clinical Practice Guideline Update

Author

Navaneethan, Sankar D., Zoungas, Sophia, Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Liew, Adrian, Michos, Erin D., Olowu, Wasiu A., Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R., Wanner, Christoph, Wilkens, Katy G., Craig, Jonathan C., Tunnicliffe, David J., Tonelli, Marcello, Cheung, Michael, Earley, Amy, Rossing, Peter, de Boer, Ian H., Khunti, Kamlesh, Navaneethan, Sankar D., Zoungas, Sophia, Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Liew, Adrian, Michos, Erin D., Olowu, Wasiu A., Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R., Wanner, Christoph, Wilkens, Katy G., Craig, Jonathan C., Tunnicliffe, David J., Tonelli, Marcello, Cheung, Michael, Earley, Amy, Rossing, Peter, de Boer, Ian H., and Khunti, Kamlesh

Abstract

Description: The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease is an update of the 2020 guideline from Kidney Disease: Improving Global Outcomes (KDIGO). Methods: The KDIGO Work Group updated the guideline, which included reviewing and grading new evidence that was identified and summarized. As in the previous guideline, the Work Group used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of recommendations and expert judgment to develop consensus practice points. New evidence led to updating of recommendations in the chapters Comprehensive Care in Patients With Diabetes and CKD (Chapter 1) and Glucose-Lowering Therapies in Patients With T2D and CKD (Chapter 4). New evidence did not change recommendations in the chapters Glycemic Monitoring and Targets in Patients With Diabetes and CKD (Chapter 2), Lifestyle Interventions in Patients With Diabetes and CKD (Chapter 3), and Approaches to Management of Patients With Diabetes and CKD (Chapter 5). Recommendations: The updated guideline includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease (CKD). A focus on preserving kidney function and maintaining well-being is recommended using a layered approach to care, starting with a foundation of lifestyle interventions, self-management, and first-line pharmacotherapy (such as sodium–glucose cotransporter-2 inhibitors) demonstrated to improve clinical outcomes. To this are added additional drugs with heart and kidney protection, such as glucagon-like peptide-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists, and interventions to control risk factors for CKD progression and cardiovascular events, such as blood pressure, glycemia, and lipids.

Published
2023

13. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update

Author

Navaneethan, Sankar D., primary, Zoungas, Sophia, additional, Caramori, M. Luiza, additional, Chan, Juliana C.N., additional, Heerspink, Hiddo J.L., additional, Hurst, Clint, additional, Liew, Adrian, additional, Michos, Erin D., additional, Olowu, Wasiu A., additional, Sadusky, Tami, additional, Tandon, Nikhil, additional, Tuttle, Katherine R., additional, Wanner, Christoph, additional, Wilkens, Katy G., additional, Craig, Jonathan C., additional, Tunnicliffe, David J., additional, Tonelli, Marcello, additional, Cheung, Michael, additional, Earley, Amy, additional, Rossing, Peter, additional, de Boer, Ian H., additional, and Khunti, Kamlesh, additional

Published
2023
Full Text
View/download PDF

15. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease:an update based on rapidly emerging new evidence

Author

Rossing, Peter, Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A., Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R., Wanner, Christoph, Wilkens, Katy G., Zoungas, Sophia, Craig, Jonathan C., Tunnicliffe, David J., Tonelli, Marcello A., Cheung, Michael, Earley, Amy, de Boer, Ian H., Rossing, Peter, Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A., Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R., Wanner, Christoph, Wilkens, Katy G., Zoungas, Sophia, Craig, Jonathan C., Tunnicliffe, David J., Tonelli, Marcello A., Cheung, Michael, Earley, Amy, and de Boer, Ian H.

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating people with diabetes and CKD. Topic areas for which recommendations are updated based on new evidence include Chapter 1: Comprehensive care in patients with diabetes and CKD and Chapter 4: Glucose-lowering therapies in patients with type 2 diabetes (T2D) and CKD. The content of previous chapters on Glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), Lifestyle interventions in patients with diabetes and CKD (Chapter 3), and Approaches to management of patients with diabetes and CKD (Chapter 5) has been deemed current and was not changed. This guideline update was developed according to an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence, and the strength of recommendations followed the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach. Limitations of the evidence are discussed, and areas for which additional research is needed are presented.

Published
2022

16. Childhood idiopathic steroid resistant nephrotic syndrome in Southwestern Nigeria

Author

Olowu Wasiu, Adelusola Kayode, and Adefehinti Olufemi

Subjects
Medicine
Abstract

Clinical charts of 23 Nigerian children diagnosed with Idiopathic Steroid Resistant Nephrotic Syndrome (iSRNS) between January 2001 and December 2007 were retrospectively re-viewed to determine their clinicopathologic characteristics and outcome. iSRNS (54.8%) was pri-mary in 19 patients (83%) and secondary in four (17%). The mean age at diagnosis was 8.3 ± 3.5 years (2.1-13 years). Histopathology revealed membranoproliferative glomerulonephritis (MPGN) in 43.5%, focal and segmental glomerulosclerosis (FSGS) in 39.1% and mesangial proliferative glo-merulonephritis in 8.7% of the patients while minimal change disease (MCD) and membranous nephropathy accounted for 4.35% each. Routine treatment protocol comprised pulse intravenous (i.v.) cylophosphamide infusion and i.v. dexamethasone ΁ lisinopril or spironolactone. Cumulative Com-plete Remission (CR) rate was 57.12%. The overall median time to CR from start of steroid sparing agents in 12/21 treated patients was 4.5 weeks. CR was better achieved in MPGN than FSGS (P = 0.0186). Five patients had eight relapses with the overall median relapse-free duration being four months. Cumulative renal survival at 36 months was 41.8%. The median follow-up duration was eight months. Our study revealed that there was a high prevalence of iSRNS and preponderance of non-MCD lesions, with MPGN and FSGS being the major morphologic lesions. The outcome with steroid and cyclophosphamide-based treatment for iSRNS was further enhanced with addition of either lisinopril or spironolactone.

Published
2010

17. The authors reply

Author

Caramori, M. Luiza, primary, Tuttle, Katherine R., additional, Tandon, Nikhil, additional, Tunnicliffe, David J., additional, de Boer, Ian H., additional, Rossing, Peter, additional, Chan, Juliana C.N., additional, Heerspink, Hiddo J.L., additional, Hurst, Clint, additional, Khunti, Kamlesh, additional, Liew, Adrian, additional, Michos, Erin D., additional, Navaneethan, Sankar D., additional, Olowu, Wasiu A., additional, Sadusky, Tami, additional, Wanner, Christoph, additional, Wilkens, Katy G., additional, Zoungas, Sophia, additional, Lytvyn, Lyubov, additional, Craig, Jonathan C., additional, Howell, Martin, additional, Tonelli, Marcello, additional, Cheung, Michael, additional, and Earley, Amy, additional

Published
2022
Full Text
View/download PDF

18. Reversible Renal Failure in Hypertensive Idiopathic Nephrotics Treated with Captopril

Author

Olowu Wasiu, Adenowo Olusola, and Elusiyan Jerome

Subjects
Cyclophosphamide, Hypertension, Oliguria, Proteinuria, Seizures., Medicine
Abstract

Angiotensin converting enzyme inhibitor (ACEI)- induced acute renal failure (ARF) is not as commonly reported in children as in adults. We report two cases of idiopathic nephrotic syndrome that developed ARF following captopril (an ACEI) treatment for prednisolone-induced hypertension. The two cases further alert us to the potential risk of ACEI-induced ARF in any nephrotic child on ACEI treatment. Low or high dose ACEIs should be given with extreme caution in active nephrotics in view of their relative hypovolemic state that may provoke ARF. The nephrotic children, who must be treated with ACEIs with or without diuretics, should be closely monitored for the development of ARF during the use of ACEIs.

Published
2006

19. Коротке резюме Настанови з клінічної практики щодо лікування цукрового діабету в пацієнтів із хронічною хворобою нирок (KDIGO) 2022 р.: оновлення на підставі нових, оперативно отриманих доказових даних.

Author

Rossing, Peter, Caramori, M. Luiza, Chan, Juliana C. N., Heerspink, Hiddo J. L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A., Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R., Wanner, Christoph, Wilkens, Katy G., Zoungas, Sophia, Craig, Jonathan C., Tunnicliffe, David J., Tonelli, Marcello A., and Cheung, Michael

Published
2022
Full Text
View/download PDF

20. Diabetes Management in Chronic Kidney Disease:Synopsis of the 2020 KDIGO Clinical Practice Guideline

Author

Navaneethan, Sankar D, Zoungas, Sophia, Caramori, M Luiza, Chan, Juliana C N, Heerspink, Hiddo J L, Hurst, Clint, Liew, Adrian, Michos, Erin D, Olowu, Wasiu A, Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R, Wanner, Christoph, Wilkens, Katy G, Lytvyn, Lyubov, Craig, Jonathan C, Tunnicliffe, David J, Howell, Martin, Tonelli, Marcello, Cheung, Michael, Earley, Amy, Rossing, Peter, de Boer, Ian H, Khunti, Kamlesh, Navaneethan, Sankar D, Zoungas, Sophia, Caramori, M Luiza, Chan, Juliana C N, Heerspink, Hiddo J L, Hurst, Clint, Liew, Adrian, Michos, Erin D, Olowu, Wasiu A, Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R, Wanner, Christoph, Wilkens, Katy G, Lytvyn, Lyubov, Craig, Jonathan C, Tunnicliffe, David J, Howell, Martin, Tonelli, Marcello, Cheung, Michael, Earley, Amy, Rossing, Peter, de Boer, Ian H, and Khunti, Kamlesh

Abstract

DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2020 for the management of patients with diabetes and chronic kidney disease (CKD).METHODS: The KDIGO Work Group (WG) was tasked with developing the guideline for diabetes management in CKD. It defined the scope of the guideline, gathered evidence, determined systematic review topics, and graded evidence that had been summarized by an evidence review team. The English-language literature searches, which were initially done through October 2018, were updated in February 2020. The WG used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of the recommendations. Expert judgment was used to develop consensus practice points supplementary to the evidence-based graded recommendations. The guideline document underwent open public review. Comments from various stakeholders, subject matter experts, and industry and national organizations were considered before the document was finalized.RECOMMENDATIONS: The guideline includes 12 recommendations and 48 practice points for clinicians caring for patients with diabetes and CKD. This synopsis focuses on the key recommendations pertinent to the following issues: comprehensive care needs, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and educational and integrated care approaches.

Published
2021

25. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline:evidence-based advances in monitoring and treatment

Author

de Boer, Ian H., Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A., Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R., Wanner, Christoph, Wilkens, Katy G., Zoungas, Sophia, Lytvyn, Lyubov, Craig, Jonathan C., Tunnicliffe, David J., Howell, Martin, Tonelli, Marcello, Cheung, Michael, Earley, Amy, Rossing, Peter, de Boer, Ian H., Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A., Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R., Wanner, Christoph, Wilkens, Katy G., Zoungas, Sophia, Lytvyn, Lyubov, Craig, Jonathan C., Tunnicliffe, David J., Howell, Martin, Tonelli, Marcello, Cheung, Michael, Earley, Amy, and Rossing, Peter

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD.

Published
2020

26. Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline

Author

Navaneethan, Sankar D., primary, Zoungas, Sophia, additional, Caramori, M. Luiza, additional, Chan, Juliana C.N., additional, Heerspink, Hiddo J.L., additional, Hurst, Clint, additional, Liew, Adrian, additional, Michos, Erin D., additional, Olowu, Wasiu A., additional, Sadusky, Tami, additional, Tandon, Nikhil, additional, Tuttle, Katherine R., additional, Wanner, Christoph, additional, Wilkens, Katy G., additional, Lytvyn, Lyubov, additional, Craig, Jonathan C., additional, Tunnicliffe, David J., additional, Howell, Martin, additional, Tonelli, Marcello, additional, Cheung, Michael, additional, Earley, Amy, additional, Rossing, Peter, additional, de Boer, Ian H., additional, and Khunti, Kamlesh, additional

Published
2021
Full Text
View/download PDF

27. Management of idiopathic childhood nephrotic syndrome in sub-Saharan Africa: Ibadan consensus statement

Author

Esezobor, Christopher, primary, Ademola, Adebowale D., additional, Adetunji, Adewale E., additional, Anigilaje, Emmanuel A., additional, Batte, Anthony, additional, Jiya-Bello, Fatima N., additional, Furia, Francis F., additional, Muoneke, Uzoamaka, additional, McCulloch, Mignon, additional, Nourse, Peter, additional, Obiagwu, Patience, additional, Odetunde, Odutola, additional, Okyere, Perditer, additional, Solarin, Adaobi, additional, Tannor, Elliot K., additional, Noone, Damien, additional, Gbadegesin, Rasheed, additional, Parekh, Rulan S., additional, Ashuntantang, Gloria, additional, Georgette, Guemkam, additional, Adu, Dwamoa, additional, Adabayeri, Victoria May, additional, Boima, Vincent, additional, Osafo, Charlotte, additional, Tannor, Elliot Koranteng, additional, Antwi, Sampson, additional, Plange-Rhule, Jacob, additional, Mamven, Manmak, additional, Ajayi, Samuel, additional, Anigilaje, Emmanuel, additional, Okoye, Ogochukwu, additional, Okperi, Ofejiro, additional, Ighosewe, Okiroro, additional, Ulasi, Ifeoma, additional, Okafor, Henrietta U., additional, Salako, Babatunde, additional, Ademola, Adebowale, additional, Amodu, Kemi, additional, Raji, Yemi, additional, Adanze, Asinobi O., additional, Arogundade, Fatiu, additional, Olowu, Wasiu, additional, Olanrewaju, Timothy Olusegun, additional, Adedoyin, Olanrewaju, additional, Abdu, Aliyu, additional, Amira, Oluwatoyin, additional, Esezobor, Christopher, additional, Odenigbo, Charles, additional, Jisieike-Onuigbo, Nonyelum, additional, Musa, Adesola, additional, Audu, Rosemary, additional, Jinadu, Olanrewaju, additional, Makusidi, Muhammad, additional, Jiya Bello, Fatima Nma, additional, Awobusuyi, Jacob Olugbenga, additional, Furia, Francis Frederick, additional, Ruggajo, Paschal, additional, Shoo, Jacqueline, additional, Kalyesubula, Robert, additional, Kansiime, Grace, additional, Vasilevska-Ristovska, Jovanka, additional, Banh, Tonny H.M., additional, Ojo, Akinlolu O., additional, Wilson, Jillian, additional, Smith, Donna, additional, and Ilori, Titilayo, additional

Published
2021
Full Text
View/download PDF

29. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

Author

de Boer, Ian H., primary, Caramori, M. Luiza, additional, Chan, Juliana C.N., additional, Heerspink, Hiddo J.L., additional, Hurst, Clint, additional, Khunti, Kamlesh, additional, Liew, Adrian, additional, Michos, Erin D., additional, Navaneethan, Sankar D., additional, Olowu, Wasiu A., additional, Sadusky, Tami, additional, Tandon, Nikhil, additional, Tuttle, Katherine R., additional, Wanner, Christoph, additional, Wilkens, Katy G., additional, Zoungas, Sophia, additional, and Rossing, Peter, additional

Published
2020
Full Text
View/download PDF

30. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment

Author

de Boer, Ian H., primary, Caramori, M. Luiza, additional, Chan, Juliana C.N., additional, Heerspink, Hiddo J.L., additional, Hurst, Clint, additional, Khunti, Kamlesh, additional, Liew, Adrian, additional, Michos, Erin D., additional, Navaneethan, Sankar D., additional, Olowu, Wasiu A., additional, Sadusky, Tami, additional, Tandon, Nikhil, additional, Tuttle, Katherine R., additional, Wanner, Christoph, additional, Wilkens, Katy G., additional, Zoungas, Sophia, additional, Lytvyn, Lyubov, additional, Craig, Jonathan C., additional, Tunnicliffe, David J., additional, Howell, Martin, additional, Tonelli, Marcello, additional, Cheung, Michael, additional, Earley, Amy, additional, and Rossing, Peter, additional

Published
2020
Full Text
View/download PDF

38. The authors reply

Author

Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A., Sadusky, Tami, Wanner, Christoph, Wilkens, Katy G., Zoungas, Sophia, Lytvyn, Lyubov, Craig, Jonathan C., Howell, Martin, Tonelli, Marcello, Cheung, Michael, Earley, Amy, Caramori, M. Luiza, Tuttle, Katherine R., Tandon, Nikhil, Tunnicliffe, David J., de Boer, Ian H., and Rossing, Peter

Published
2022
Full Text
View/download PDF

42. Pediatric stroke in a Nigerian child with sickle cell disease: a case report

Author

Senbanjo, Idowu O., Oseni, Saheed B.A., Aladekomo, Theophilus A., Olowu, Wasiu A., Adeodu, Olugbenga, and Oyedeji, Gabriel A.

Subjects
Stroke (Disease) -- Case studies, Stroke (Disease) -- Care and treatment, Blood transfusion -- Usage, Sickle cell anemia -- Complications and side effects, Sickle cell anemia -- Care and treatment, Sickle cell anemia in children -- Case studies, Sickle cell anemia in children -- Care and treatment, Children -- Diseases, Children -- Case studies, Children -- Care and treatment, Health
Abstract

Abstract A nine and half year old girl with sickle cell disease (HbSC) developed stroke following a febrile illness. The diagnosis was clinical, as CT scan was not done. She [...]

Published
2006

46. Childhood-onset systemic lupus erythematosus

Author

Olowu, Wasiu

Subjects
Male, Adolescent, Prednisolone, Anti-Inflammatory Agents, Humans, Lupus Erythematosus, Systemic, Nigeria, Female, Prospective Studies, Age of Onset, Child, Cyclophosphamide, Research Article
Abstract

OBJECTIVES: To describe the initial clinicolaboratory manifestations and short-term outcome in a series of Nigerian children with systemic lupus erythematosus (SLE). METHODS: A nonrandomized prospective study of consecutive cases of childhood-onset SLE. Baseline and follow-up clinicolaboratory data were collected and analyzed. Each patient was followed up for 12 months. RESULTS: Eleven children were studied. There were seven girls (F:M, 1.75). Mean ages at lupus onset and diagnosis were 10.0 +/- 2.53 years and 11.2 +/- 2.53 years, respectively. Mean time at onset of renal disease following SLE symptoms onset was 1.22 +/- 0.93 years. All cases were misdiagnosed prior to presentation; diagnosis was delayed in nine patients. Lupus activity was mild, moderate and severe in two, five and four patients, respectively. Hypertension (n = 5), nephrotic syndrome (n = 6), microerythrocyturia (n = 6) and acute renal failure (n = 7) were associated morbidities. Of the 27 presenting clinical features, 17 were nondiagnostic, while 10 were diagnostic. Fever (n = 9) was a major nondiagnostic symptom; major diagnostic manifestations were lupus nephritis (n = 11), arthritis (n = 10) and serositis (n = 7). Catastrophic antiphospholipid syndrome was diagnosed in three. The glomerular lesions were nonproliferative (n = 1), focal (n = 3) and diffuse (n = 7) proliferative lupus nephritis. Complete remission rate at end-point was 71.4%. Fourteen percent of the patients relapsed. Renal survival and mortality rates were 86.0% and 30.0%, respectively. CONCLUSION: In this study, severe renal and extrarenal comorbidities were common; mortality rate was also high. High frequency of misdiagnosis and delayed diagnosis were probably responsible for these.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results